3 High Growth Tech Stocks in Australia to Watch

In the last week, the Australian market has stayed flat, but it is up 17% over the past year with earnings expected to grow by 12% per annum over the next few years. In this context of steady growth and positive earnings outlook, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and have a clear path to expanding their market presence.

Top 10 High Growth Tech Companies In Australia

Name	Revenue Growth	Earnings Growth	Growth Rating
Clinuvel Pharmaceuticals	22.32%	27.42%	★★★★★★
Adherium	86.80%	73.66%	★★★★★★
ImExHS	20.47%	111.20%	★★★★★★
Telix Pharmaceuticals	20.10%	38.31%	★★★★★★
AVA Risk Group	32.56%	118.83%	★★★★★★
Careteq	37.17%	126.21%	★★★★★☆
Pointerra	56.62%	126.45%	★★★★★★
Wrkr	36.31%	100.29%	★★★★★★
Adveritas	57.98%	144.21%	★★★★★★
SiteMinder	19.40%	60.64%	★★★★★☆

Click here to see the full list of 64 stocks from our ASX High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Mesoblast (ASX:MSB)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited is a company focused on developing regenerative medicine products across Australia, the United States, Singapore, and Switzerland with a market capitalization of A$1.70 billion.

Operations: The company generates revenue primarily through the development of its cell technology platform, with reported earnings of $5.90 million.

Amidst a challenging landscape, Mesoblast Limited (MSB) is navigating through unprofitability with strategic initiatives aimed at reversing its fortunes. The company's revenue is expected to surge by 45.8% annually, outpacing the Australian market's average growth of 5.5%. This projection aligns with MSB's recent entry into a $50 million convertible note agreement, potentially bolstering its financial runway despite current cash constraints under one year. However, shareholders have faced dilution over the past year, reflecting ongoing capital needs amidst efforts to transition into profitability within three years—a goal supported by anticipated annual profit growth surpassing market norms.

• Dive into the specifics of Mesoblast here with our thorough health report.

• Explore historical data to track Mesoblast's performance over time in our Past section.

Pro Medicus (ASX:PME)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe with a market cap of A$18.71 billion.

Operations: The company generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$161.50 million.

Pro Medicus stands out in the Australian tech landscape, demonstrating robust financial health and growth prospects. Over the past year, the company's earnings surged by 36.5%, significantly outpacing the Healthcare Services industry's growth of 13.3%. This performance is underpinned by a strategic focus on R&D, with expenses consistently aligned to drive innovation—evident from their recent revenue increase to AUD 166.33 million from AUD 127.33 million a year ago. Looking ahead, Pro Medicus is expected to see its earnings grow annually by 18.8%, well above Australia's market average of 12.2%, positioning it favorably for sustained advancements in medical imaging technology. Recent dividends reflect this upward trajectory with a notable increase to AUD 0.40 per share fully franked, up by 33.3% from last year, signaling strong profit returns and shareholder confidence amidst broader market challenges. Moreover, Pro Medicus’s commitment to reinvesting in its core capabilities suggests continued industry leadership and potential for further market penetration, especially as global demand for advanced healthcare solutions escalates.

• Click to explore a detailed breakdown of our findings in Pro Medicus' health report.

• Learn about Pro Medicus' historical performance.

REA Group (ASX:REA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: REA Group Limited operates an online property advertising business across Australia, India, the United States, Malaysia, Singapore, Thailand, Vietnam, and other international markets with a market capitalization of A$28.03 billion.

Operations: The company generates revenue primarily from property and online advertising in Australia (A$1.25 billion), financial services in Australia (A$320.60 million), and its operations in India (A$103.10 million). The business focuses on leveraging digital platforms to connect property seekers with real estate opportunities, contributing to its diverse revenue streams across multiple regions.

REA Group, a significant entity in Australia's tech scene, is navigating through a challenging landscape with strategic agility. Despite a recent dip in net income from AUD 356.1 million to AUD 302.8 million, the company's commitment to innovation and growth remains evident through its R&D initiatives and revenue forecasts. Expected to outpace the Australian market with a revenue increase of 6.5% annually compared to the market's 5.5%, REA also anticipates earnings growth of 16.8% per year, showcasing resilience and potential for recovery. Moreover, an increased dividend payout of AUD 1.02 per share reflects confidence in future profitability and shareholder value enhancement amidst evolving market dynamics.

• Click here and access our complete health analysis report to understand the dynamics of REA Group.

• Gain insights into REA Group's past trends and performance with our Past report.

Taking Advantage

• Reveal the 64 hidden gems among our ASX High Growth Tech and AI Stocks screener with a single click here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com